Benchmark

Benchmark reiterates its Buy rating on Synergetics USA (NASDAQ: SURG) but lowers the price target to $7. Benchmark says, "Management sees visibility to strong results in F4Q due to unusual factors that may not support future periods. We conservatively trimmed our out-year forecast to reflect a...

In a report published earlier today, Benchmark reiterated its Buy rating and $7.50 price target for CryoLife, Inc. (NYSE: CRY). Benchmark went on to say “CryoLife's strategy is to generate substantial long term value by strengthening and leveraging market leading sales forces in cardiac and...

Benchmark reiterates its Neutral rating on Abbott Laboratories (NYSE: ABT) but raises its price target from $60 to $62. Benchmark notes, "We've updated our Abbott model to reflect the additional disclosures in the company's Form 10 released Monday (June 4) ahead of the AbbVie spin...

Benchmark reiterates its Hold rating on The Pep Boys - Many Moe & Jack (NYSE: PBY) but lowers its price target to $9 a share. Benchmark notes, "Pep Boys is expected to report Q1 earnings Thursday, June 7 before the market open. This would be management's first conference call since the...

Benchmark remains rated Buy with a $20 price target on Groupon (NASDAQ: GRPN) after they met with the company's investor relations in Chicago. Benchmark comments, "We visited Groupon's Chicago sales office and met with investor relations last week. We have three takeaways: 1) The IPO lock-up,...

According to a research report published this morning, Benchmark has lowered Big Lots' (NYSE: BIG) PT from $50 to $45. In the report, Benchmark said, "Big Lots' Q1 EPS was $0.68, versus our and consensus estimate of $0.69, after the Company pre-announced a weakness in comps. While we maintained...

According to a research report published this morning, Benchmark has lowered McGraw-Hill Companies' (NYSE: MHP) PT from $52 to $50. In the report, Benchmark said, "US and Euro denominated investment grade and high yield bond issuance has slowed materially in recent weeks, based on industry...

According to a research report published this morning, Benchmark has lowered American Science & Engineering's (NASDAQ: ASEI) PT from $66 to $58. Benchmark mentioned in the report, "AS&E reported Q4FY12 revenue and EPS of $39.8 million, down 41% y/y, and $0.15, significantly lower than...

According to a research report published this morning, Benchmark has lowered Groupon's (NASDAQ: GRPN) PT from $28 to $20. Benchmark said in the report, "Groupon reported 1Q12 results and 2Q12 guidance that topped expectations. Operating metrics showed no sign of competitive pressure, with a 41%...

According to a research report published this morning, Benchmark has increased Vitacost.com's (NASDAQ: VITC) PT from $7 to $8. Benchmark commented, "Vitacost (VITC-Hold, PT from $7 to $8) reported better than expected revenue of $83.6 million, up 31% y/y, well ahead of consensus at $76.3 million...

According to a research report published this morning, Benchmark has upgraded The E.W. Scripps Company (NYSE: SSP) from Hold to Buy, and raised PT from $10.50 to $11. Benchmark said in the report, "We are upgrading E.W.Scripps (SSP) from Hold to Buy and raising our target price from $10.50 to $11...

According to a research report published this morning, Benchmark has initiated Smith & Wesson (NASDAQ: SWHC) with a Buy rating and $9 PT. In the report, Benchmark said, "Our price target is based on an 8.5x FY13 EV/EBITDA multiple, which we believe is appropriate for an industry leader well...

According to a research report published this morning, Benchmark has initiated Sturm, Ruger & Company (NYSE: RGR) with a Buy rating and $60 PT. In the report, Benchmark commented, "Our price target is based on a 10x FY12 EV/EBITDA multiple, which we believe is appropriate for an industry...

Following a massive ~40% drop in shares after market close yesterday, it may be surprising to some that Fossil (NASDAQ: FOSL) has climbed back up, trading +1% for the day thus far. With controversy buzzing around the stock's weak European numbers and a pending acquisition, it appears that this...

According to a research report published this morning, Benchmark has initiated Vascular Solutions (NASDAQ: VASC) with a Buy rating and $15 PT. In the report, Benchmark said, "We are initiating coverage of Vascular Solutions (VASC) with a Buy rating and a twelve month price target of $15.00. Our $...